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Introduction: The miR-183/-96/-182 cluster is a conserved polycistronic microRNA (miRNA) cluster which is highly
expressed in most breast cancers. Although there are some sporadic reports which demonstrate the importance
of each miRNA in this cluster in breast cancer, the biological roles of this cluster as a whole and its regulation
mechanisms in breast cancer are still unclear. We compared the expression of this cluster in different cancer types,
analyzed the regulation mechanism of this cluster, identified new target genes, and examined the impact of this
cluster on breast cancer cells.
Methods: The miRNA level was detected by LNA-based northern blot and Real-time PCR, and was also analyzed
from TCGA dataset. Bioinformatics research and luciferase assay were applied to find the promoter regions and
transcription factors. To investigate the biological effects of the miR-183/-96 /-182 cluster in breast cancer, we
generated miR-96, miR-182 and miR-183 overexpression stable cell lines to check the overdose effects; we also
used miR-Down™ antagomir for each miRNA as well as miR-183/-96 /-182 cluster sponge lentivirus to check the
knockdown effects. Growth, migration, cell cycle profile and survival of these cells was then monitored by colony
formation assay, MTT assay, cell wound healing assay, flow cytometry and microscopy. The target gene was
validated by Real-time PCR, luciferase assay, Western blot and Phalloidin/DAPI counterstaining.
Results: The miR-183/-96/-182 cluster was highly expressed in most breast cancers, and its transcription is disordered
in breast cancer. The miR-183/-96/-182 cluster was transcribed in the same pri-miRNA and its transcription was
regulated by ZEB1 and HSF2. It increased breast cell growth by promoting more rapid completion of mitosis, promoted
cell migration and was essential for cell survival. MiR-183 targeted the RAB21 mRNA directly in breast cancer.
Conclusion: The miR-183/-96/-182 cluster is up-regulated in most breast cancer. It functions as an oncogene in breast
cancer as it increases cell proliferation and migration.Introduction
Breast cancer is a family of diseases that involve unregu-
lated breast epithelial cell growth and division, which is
caused by many different carcinogenic factors. The exact
cause of breast cancer is unclear. Many risk factors may
increase the chance of having breast cancer, such as
endocrine disorders, genetic mutations and declines in
immune function. However, unregulated mammary epi-
thelial cell proliferation and apoptosis, which are caused* Correspondence: biqbz@hotmail.com
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unless otherwise stated.by an accumulation of gene mutations and by dysregu-
lated gene expression, is the essential reason for breast
cancer. As numerous genes are predicted to be regulated
by microRNA (miRNA), mammary tumorigenesis and
metastasis is likely to be regulated by several tissue-
specific miRNAs.
The miR-183/-96/-182 cluster is a highly conserved
polycistronic miRNA cluster which was first identified
by Dr Xu in sensory organs [1]. Members of this cluster
are located within a 5-kb region on human chromosome
7q32.2 and are transcribed in the same direction from
telomere to centromere. Previous studies showed that
the miR-183/-96/-182 cluster is abnormally expressed inhis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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cancers. But the role of this miRNA cluster in tumors is
still unclear. It may function as an oncogene or tumor
suppressor gene, depending on the type, location and
stage of the cancer. We summarize its reported func-
tions in cancers and its target genes in Table 1.
The miR-183/-96/-182 cluster has not yet been exten-
sively studied in breast cancer. Forkhead box O (FOXO)
proteins, which are a family of tumor suppressor tran-
scription factors involved in cell growth, proliferation,
differentiation, and longevity, are the main targets for
this cluster in breast cancer. Both FOXO1 and FOXO3a
are regulated by miR-96 and miR-182 [5,6]. It seems that
this miRNA cluster functions as onco-microRNA in
breast cancer. However, in 2010, Lowery et al. reported
that miR-183 inhibits cell migration in breast cancer by
repressing Ezrin, which plays a key role in cell-surface
structure adhesion, migration, and organization [12].
These conflicting results may be ascribed to two reasons.
One possibility is that these three miRNAs are tran-
scribed or processed in different way and they function
separately and differently; the other possibility is that
this cluster plays different roles in different breast cancer
types. In fact, the level of miR-183 was lower in estrogen
receptor (ER)-positive breast tumors compared to ER-Table 1 Role of miR-183/-96/-182 in cancer based on recent p
miRNA Oncogene/tumor suppressor Cancer type Funct
miR-96 Oncogene Hepatocellular carcinoma Increa
colony
miR-96 Oncogene Prostate cancer Inhibit
miR-182
miR-183




miR-96 Oncogene Breast cancer Induce
miR-96 Oncogene Breast cancer Increa
miR-182
miR-182 Oncogene Glioma Promo
miR-182 Oncogene Melanoma Promo
and su
miR-183 Oncogene Synovial sarcoma Promo
miR-183 Oncogene Hepatocellular carcinoma Iinhibi
apopt
miR-96 Tumor suppressor Pancreatic cancer Decre
migra
miR-183 Tumor suppressor Breast cancer Inhibit
miR-183 Tumor suppressor Osteosarcoma Inhibit
miR-182 Tumor suppressor Lung cancer Inhibitnegative tumors, and higher in human epidermal growth
factor receptor-2 (HER2)/neu-receptor-positive tumors
compared to HER2/neu-receptor-negative tumors [12],
suggesting the roles of miR-183 in different breast cancer
cells are different.
Recently, attention has focused on the target genes of
these miRNAs; however, little is known about the regu-
lation mechanism of the miRNA cluster itself. Most
miRNA genes are transcribed by RNA polymerase II
[15], which means miRNA biogenesis is controlled
elaborately through various regulatory pathways just as
protein-coding mRNAs. Chromatin structure analysis,
genomic and RNA sequence analysis and RNA polymer-
ase II chromatin immuneprecipitation assays have been
applied to predict the transcription start site (TSS) and
promoter region of miRNAs [16-19], but few results have
been confirmed by experiments. The Ozsolak [16], Wang
[18], and Chien [19] laboratories predicted that the TSS of
miR-183/-96/-182 was 5068 bp, 5200 bp and 5207 bp up-
stream of the miR-183 precursor, respectively. However,
the promoter region of miR-183/-96/-182 and the tran-
scription regulators remain unknown.
Here, we investigated the function of the miR-183/-
96/-182 cluster in breast cancer. We found that the miR-
183/-96/-182 cluster was highly expressed in most breastublications within the last five years
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same pri-miRNA and this miRNA cluster was regulated
by HSF2 and ZEB1. We also demonstrated that the miR-
183/-96/-182 cluster functioned as an onco-miRNA in
breast cancer. Overexpression of the miR-183/-96/-182
cluster increased the cell proliferation rate and promoted
cell migration while inhibition of the miR-183/-96/-182
cluster decreased cell growth rate, and even induced cell
death. MiR-183 targeted RAB21 directly in breast cancer
and accumulated nucleus number aberration cells. Our
results suggested that the miR-183/-96/-182 cluster plays
an important role in tumorigenesis and in the migration
of breast cancer cells.
Methods
Clinical cancer samples and cell lines
All cancer samples were obtained from the Affiliated
Tumor Hospital of XiangYa Medical School of Central
South University, and stored at -80°C until analyzed. All
experiments were conducted in accordance with the
Declaration of Helsinki and were approved by the Xiangya
Hospital Medical Ethics Committee in Central South
University.
Breast cancer cell lines MCF-7,MDA-MB-231,SK-BR-3,
T47D, ZR-75-1, MCF-10A and human embryonic kidney
cell HEK-293 were used in the study. MCF-7 and MDA-
MB-231 were obtained from NeuronBiotech (Shanghai,
China). SK-BR-3, T47D, ZR-75-1 and MCF-10A were ob-
tained from Dingguo, Co. (Beijing, China). HEK-293 was
obtained from Xiangya experiment center (Changsha,
China). All the cells were cultured in complete DMEM
high glucose medium (Hyclone, Logan, UT, USA) supple-
mented with 10% FBS (Hyclone) and 1% penicillin and
streptomycin sulfate (Solarbia, Co., Beijing, China). Cells
were incubated at 37°C with 5% CO2 and medium was
changed every 2 or 3 days.
Virion and cell line constructions
To establish the miRNA overexpression cell lines, partial
mir-96, mir-182 and mir-183 pri-microRNA sequences
flanked by EcoRI and AgeI restriction sites were inserted
into the CMV promoter of lentivirus infectious virions
pLKD-CMV-G&PR-U6-shRNA (Hpcoo3) (Additional file 1:
Figure S1A). MCF-7 or T47D cells were infected with
these viruses and selected under the pressure of 1 μg/ml
puromycin (Invitrogen, San Diego, CA, USA). The green
fluorescent protein (GFP) signal of the infected cells was
detected under microscope (Additional file 1: Figure S1B),
and the expression of the miR-183/-96/-182 cluster in
each cell line was measured by reverse transcription (RT)-
PCR (Additional file 1: Figure S1C).
To disrupt the activity of the miR-183/-96/-182 cluster,
we generated miR-183/-96/-182 cluster sponge lenti-
virus virion. Basically, 10 copies each of complementarysequences to miR-183, miR-96 and miR-182, each with
mismatches at positions 9 to 12 for improved stability
[20,21], were introduced into the pLOV-CMV-eGFP-
EF1a-PuroR lentivirus infective virion (Additional file 2:
Figure S2). A moderate multiplicity of infection (MOI) of
1 was used for transduction. The infection efficiency and
cell morphology were monitored under microscope every
day. After 3 days of transduction, cells were collected
for cell cycle analysis and RNAs were collected for real-
time PCR.
To research the function of transcription factors, the
coding sequences of HSF2 and ZEB1 flanked by XhoI
and KpnI restriction sites were inserted into vector
GV219. The plasmids were transfected into MCF-7 cells
and the cells were selected with a culture medium con-
taining 600 μg/ml G418-Geneticin (GenView, Galveston,
TX, USA) for 2 months.
LNA-based Northern Blotting
Total RNAs were extracted from cancer samples with the
mirVanaTM miR isolation kit and 10 μg of total RNA was
used for each assay. All procedures followed manufac-
turer’s instructions for the miRCURY LNA™ microRNA
detection probes (Exiqon, Woburn, MA, USA). After
fractionation by electrophoresis on a denaturing 12%
polyacrylamide gel containing 8 M urea, RNAs were trans-
ferred to Nytran N membrane (Amersham Biosciences,
Piscataway, NJ, USA) and fixed by UV crosslinking. Blots
were prehybridized for 1 h at 45°C in PerfectHyb™ Plus
Hybridization Buffer (Sigma, St Louis, MO, USA) and
hybridized overnight at 45°C in hybridization buffer con-
taining 0.1 nM probe, then washed twice for 30 minutes at
65°C in 0.1SSC/0.1% SDS. As the probes were 5′-DIG la-
beled, we detected the signal by PhototopeR-Star Kit (New
England BioLabs Inc, Ipswich, MA, USA), and the dens-
ities were quantified by the Image J program. Because the
miR-183, miR-96 and miR-182 sequences are similar, we
tested the probe specificities before doing the experiments
(Additional file 3: Figure S3). Mimic oligonucleotides
were designed based on miRNA sequences registered
in the miRBase Sequence Database (see Additional file 4:
Table S1).
RT-PCR and real-time PCR
For mRNA RT-PCR and real-time PCR, total RNAs were
extracted from cancer samples or cultured cells with
Trigol (Dingguo, Co.) reagent. Primer sets were designed
within the exon junction areas listed in Additional file 4:
Table S2. For miRNA real-time PCR, miRNAs were ex-
tracted from cells using a mirVana miRNA isolation kit
(Ambion, Austin, TX, USA). All primers, including the
YRBIO™ miRNA qPCR Detection primer sets and U6
snRNA PCR primer set were purchased from Yingrun
Biotechnology (Changsha, China).
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with an M-MLV First Strand kit (Invitrogen). Then
50 ng cDNA was mixed with All-in-one™ qPCR Mix
(Genecopoeia, Rockville, MD, USA) and the target
gene primer set (final concentration: 1 μM for each pri-
mer) to produce a 20-μl reaction mixture. All real-time
PCR experiments were carried out with an ABI Step
One Plus Real-time PCR System (Applied Biosystems,
Carlsbad, CA, USA). All real-time PCR reactions were
done in triplicates, and the average ΔCT (Δ cycle thresh-
old) for the triplicates was used in subsequent analysis.
Plasmid, miR-Down™ antagomir and transfection
Large-scale plasmids were extracted by PureYield™ Plas-
mid Midiprep System (Promega, Madison, WI, USA), and
small-scale plasmids were extracted by Mini DNA purifi-
cation kit (Dingguo). Chemically modified antisense oligo-
nucleotides (miR-Down™ antagomir, GenePharm Co. Ltd,
Shanghai, China) were used to inhibit miR-96, miR-182
and miR-183 expression. A scrambled oligonucleotide was
used as control. Plasmid and miR-Down™ antagomir
transfections were conducted with Lipofectamine™ 2000
reagent (Invitrogen).
Luciferase reporter assays
For promoter analysis, promoter region sequences or
their mutants flanked by XhoI and KpnI restriction sites
were inserted into the upstream region of luciferase
reporter gene in pGL3-Basic vector (Promega). MCF-7
cells were transfected with 200 ng reporter construct and
1 μg GV219 vector with or without transcription factor
sequence. Also, 40 ng of pRL-CMV-Renilla plasmid was
transfected as an internal control.
For target analysis, 33 bp of RAB21 3′-UTRs including
the seed sequence were flanked by XbaI and FseI restric-
tion sites and inserted between the Luciferase coding
sequence and SV40 polyadenylation element in pGL3-
Promoter vector (Promega). HEK-293 cells were trans-
fected with 200 ng reporter construct and 1 μg Hpcoo3
vector with or without partial pri-microRNA sequence
of miR-183/-96/-182 cluster. Also, 40 ng of pRL-CMV-
Renilla plasmid was transfected as an internal control.
The luciferase reporter assays (Promega) were perfor-
med 48h after transfection, and luciferase activity was de-
termined with a GloMax 20/20 Luminometer (Promega).
Relative luciferase activities were calculated as ratios of
firefly to renilla luciferase activities.
Assays: 3-(4, 5-dimethyl-2-thiazolyl)-2, 5-diphenyl-2H-
tetrazolium bromide (MTT)
Cells were seeded on 96-well plates (5 × 103 cells per
well) and incubated for 24 h in 0.2 ml medium. After
reaction with 20 μl 5 mg/ml sterile MTT (Sigma) for 4 h at
37°C, culture media was removed and 150 μl of dimethylsulphoxide (DMSO) was added. The absorbance was mea-
sured with the ELISA reader (BioTek, Vermont, VT, USA)
at 490 nm and 540 nm and the reactions were performed
in triplicates.
Cell wound-healing assays
Cells were seeded on 6-well plates (5 × 105 cells per well)
and incubated for 24 h. Adherent cell monolayers were
scratched with a 10-μl pipette tip and cultured in 2 ml
DMEM high-glucose medium without FBS or antibiotics.
Cell migration was monitored under microscopy later.
Colony formation assays
The culture dish was covered by 2 ml bottom gel (0.5%
basic agar in RPMI medium 1640 (Invitrogen) supple-
mented with 10% FBS and 1% penicillin/streptomycin)
and 1.5 ml top gel (0.7% agar in RPMI-1640 medium
supplemented with 10% FBS and 1% penicillin/strepto-
mycin) mixed with 10,000 cells. Cells were incubated for
16 days and the colonies were stained with 0.5ml 0.005%
crystal violet overnight followed by washing with PBS
(Hyclone) three times. The pictures of cell colonies were
taken by a digital camera.
Cell cycle analysis
Cells were digested with 0.05% trypsin (Thermo Scientific,
Logan, UT, USA) for 2 minutes to dissociate them
from the plates. After fixation in 70% pre-chilled (−20°C)
ethanol in PBS at 4°C overnight, cells were treated
with 10 μg/ml of RNase (Auragene, Co., Shenzhen, China)
in PBS at 37°C for 2 h and stained with 50 μg/ml of propi-
dium iodide (PI) (Sigma) for 5 minutes. Flow cytometry
was conducted on a BD FACSCalibur flow cytometer
(BD Biosciences, Franklin, IN, USA) and data were ana-
lyzed by ModFit LT software.
Western blotting
Total proteins were lysed in RIPA buffer (150 mM NaCl,
0.1% SDS, 0.5% sodium deoxycholate, 1% NP-40 and 50
mM Tris-HCl, pH 7.6) with a proteinase inhibitor cock-
tail (Roche, Mannheim, Germany). After separation by
15% polyacrylamide gels and transfer to 0.45 μm mem-
brane (Millipore, Billerica, MA, USA), proteins were de-
tected by anti-RAB21 (Abcam, HongKong, China) and
anti-β-tubulin (Sigma) antibodies.
Phalloidin and 4',6-diamidino-2-phenylindole (DAPI) staining
For imaging of fixed cells, cells were seeded on acid-
washed, glass coverslips coated with 5 μg/ml of collagen.
Cells were then fixed with 3.7% paraformaldehyde in
PBS permeabilized with 0.2% Triton X-100 in PBS for 15
minutes. Then we co-stained the cells with fluorescein
isothiocyanate (FITC)-conjugated phalloidin (Beyotime,
Shangai, China) to detect the F-actin, and with DAPI
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mounted with Microscopy Aquatex® mounting medium
(Merck, Darmstadt, Germany), and then detected under
the Leica Tcs-sp5-II confocal microscope (Leica, Wetzlar,
Germany).
Statistical analysis
Data were expressed as means ± SD, and the statistical
software SPSS 11.5 (IBM, Armonk, NY, USA) was used
for analysis of variance (ANOVA) and analysis using
Student’s t-test. Statistical probability (P) in tables, figures,
and figure legends are expressed as follows: *P <0.05,
**P <0.01, *** P <0.001.
Results
The miR-183/-96/-182 cluster was highly expressed in most
breast cancers
Six different tumors and their normal adjacent tissues
(NAT) were collected from the Hunan Tumor Hospital.Figure 1 MiR-183/-96/-182 cluster is highly expressed in breast cance
LNA-based northern blot in different cancer samples and their normal adja
miR-183/-96/-182 cluster miRNAs; 5S-r RNA was used as an internal control.
program. The results were normalized to the 5S-r RNA. (B) Statistical analys
TCGA dataset: upper panel compares the miRNA expression levels between
analyzes the correlation between miR-182 and miR-183 levels in normal and
the miR-183/-96/-182 cluster miRNAs by real-time PCR in different breast ca
as internal control. Error bars indicate SD (n = 3).Breast cancer and liver cancer tumors were available
from two patients, and other types of cancer were from
one patient. The miRNAs were detected by LNA-based
northern blot. We found that miR-96, miR-182 and miR-
183 expression levels were dramatically higher in tumors
compared to the normal adjacent tissues in breast, lung
and liver cancers. MiR-96 was also expressed in thyroid
and larynx cancers, but the expression differences be-
tween tumors and their normal adjacent tissues were
not obvious. The expressions of these three miRNAs
were undetectable in other carcinoma tissues (Figure 1A).
We then performed an analysis of miRNA expression data
detected by either IlluminaGA_miRNASeq or IlluminaHi-
seq_miRNASeq in breast invasive carcinoma from the
TCGA dataset. From 102 matched pairs of samples
(Additional file 5), we found the expression levels of
miR-96, miR-182 and miR-183 in tumor samples were
increased 8.4 (± 1.1)-fold, 4.2 ± (1.1)-fold and 7.5 ± (1.1)-
fold respectively compared to the matched normalr cells. (A) Detection of miR-183/-96/-182 cluster miRNAs by
cent tissues (NAT). Left panel shows the northern blot analysis of
Left panel is the quantification of selected miRNAs by the Image J
is of miRNA expression data in breast invasive carcinoma from the
tumor samples and their matched normal samples; lower panel
tumor samples. Error bars indicate SD (n = 102). (C) Quantification of
ncer cell lines. MCF-10A cell was used as control. U6 snRNA was used
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phenomenon was that the expression levels of miR-183
and miR-182 were highly correlated in normal samples
(R2 = 0.9127), but the correlation dropped dramatic-
ally in tumor samples (R2 = 0.5475), which indicated that
the transcription pattern was changed in breast cancer
(Figure 1B, lower panel).
Because breast cancer is a heterogeneous disease
comprising different subtypes that vary significantly
with regard to clinical features and molecular markers,
we compared the miRNAs expression levels in different
breast cancers based on their clinical features, surface
markers and clinical stages. From 990 samples (Additional
file 6), we found the expressions of miR-96 and miR-183
were lower in lobular carcinoma than in ductal carcinoma
and other types of carcinoma, but the expression of miR-
182 was not correlated with the clinical features (Table 2).
The levels of miR-96 and miR-183 were also lower in
ER+ and PR+ cancers than in ER− and PR− cancers, but
miR-182 was almost the same, even slightly higher in ER+
cancers. We did not find any correlation between the
miR-183/-96/-182 cluster level and the HER2/neu recep-
tor (Table 3). The expression of miR-183/-96/-182 cluster
was not correlated with clinical stages, as all the three
miRNAs remained the same in all clinical stages (Table 4).
To divide the breast cancer samples into different sub-
types, the following surface markers were used: luminal A
(ER+ and/or PR+, HER2−), luminal B (ER+ and/or PR+,
HER2+), basal-like (ER−, PR−, HER2−), HER2-enriched
(ER−, PR−, HER2+) [22]. We found miR-96 and miR-183
levels were higher in HER2-enriched breast cancers than
other types. In basal-like breast cancers, miR-182 was
lower but miR-183 was higher comparing to other types
of breast cancer (Table 5). All these data indicated that
although miR-183/-96/-182 cluster was up-regulated in
most breast cancers, its expression pattern was slightly dif-
ferent in different breast cancer subtypes.
To confirm our findings, we also compared the miR-
NAs levels in different breast cancer cell lines based on
their ER, PR and HER2/neu receptor status. T47D
(ER+/PR+/HER2−), SK-BR-3 (ER−/PR−/HER2+), MD-
MBA-231 (ER−/R−/HER2−), ZR-75-1 (ER+/PR+/HER2+),
BT-20 (ER−/PR−/HER2−) and MCF-7 (ER+/PR+/HER2-)
cell lines were tested in this study and normal humanTable 2 Correlation between miRNA levels and clinical featur
miR-96 (per million)
Ductal (n = 734) 43.0 ± 34.4
Lobular (n = 163) 36.6 ± 28.8*
Mixed (n = 28) 37.6 ± 26.1
Other (n = 63) 49.1 ± 41.2
The expression of each miRNA in the miR-183/-96/182 cluster in different breast can
the first column. Data are presented as mean ± SD. Statistical probability (P) was exmammary epithelial cell line (MCF-10A) were used as a
control. We found that, relative to MCF-10A cell expres-
sion levels, miR-96 was only up-regulated in SK-BR-3 and
BT-20 cells; miR-182 and miR-183 were up-regulated in
most of the breast cancer cell lines except MD-MBA-231;
none of the miRNAs in the miR-183/-96/-182 cluster was
increased in MD-MBA-231 cell line (Figure 1C). Our data
were similar to those reported by Riaz et al. [23], who also
found that the highest expression of miR-96 was SK-BR-3
and the lowest expression of all these three miRNAs
was MD-MBA-231 among these six breast cancer cell
lines. We chose MCF-7 and T47D cells for further studies
because their miR-183/-96/-182 clusters were highly ex-
pressed and they were easy to culture.
MiR-183/-96/-182 cluster was transcribed in the same
pri-miRNA and was regulated by ZEB1 and HSF2
To study the regulation mechanism of the miR-183/-96/-
182 cluster itself, we first analyzed the upstream sequence
of the miR-183/-96/-182 cluster through the ENCODE
project. We found a highly conserved region from 5054
bp to 9324 bp upstream of the human miR-183 precursor
(Figure 2A, red box). The ENCODE project displayed the
acetylation of histone H3 and the transcription factor
chromatin immunoprecipitation (Chip) data to find the
active regulatory elements. H3K27Ac histone marks were
enriched in this region, which demonstrates that this re-
gion contains active regulatory elements. Transcription
factor Chip data also showed that this region was easily
pulled down with transcription factors. Altogether the
information suggested that the promoter region and TSS
of the miR-183/-96/-182 cluster is in this region.
Then, to check whether miR-183, miR-96 and miR-182
were transcribed in the same pri-miRNA or separately,
we designed a series of primer pairs (Additional file 4:
Table S3) to determine whether the corresponding regions
of DNA were transcribed. Each primer pair spanned about
1600 bp and all the primer pairs divided the genomic
DNA surrounding the miR-183/-96/-182 cluster (5352 bp
upstream to 5893 downstream of human miR-183 precur-
sor) into eight regions. From 5′-end to 3′-end, they were
named Seq#1, Seq#2 … Seq#8 (their relative locations
are showed in Figure 2B, upper panel). Total RNAs were
extracted from MCF-7, T47D and MCF10A cell lines.es
miR-182 (per million) miR-183 (per million)
48741.7 ± 33619.5 20501.7 ± 15436.4
51136.1 ± 37893.2 14014.1 ± 9845.4***
44265.7 ± 22469.4 15781.5 ± 10831.5
50700.0 ± 38025.3 19988.6 ± 17839.2
cer subtypes is based on their clinical features: Patient number is indicated in
pressed as *P<0.05, ***P<0.001.
Table 3 Correlation between miRNA levels and surface markers
miR-96 (per million) miR-182 (per million) miR-183 (per million)
ER− (n = 185) 46.9 ± 37.1 42764.4 ± 29615.6 23463.0 ± 18606.7
ER + (n = 643) 40.5 ± 32.2* 49378.5 ± 32671.3* 17756.8 ± 12451.0***
PR− (n = 265) 45.6 ± 34.7 45513.2 ± 32873.7 22037.2 ± 16212.9
PR + (n = 561) 40.2 ± 32.8* 49013.4 ± 31716.4 17628.8 ± 12993.5***
HER2− (n = 512) 40.7 ± 34.5 47943.7 ± 32825.1 18532.7 ± 14331.1
HER2+ (n = 144) 41.8 ± 32.5 44664.8 ± 28806.9 19404.0 ± 14591.3
The expression of each miRNA in the miR-183/-96/182 cluster in different breast cancer subtypes based on their surface markers: Patient number is indicated in the first
column. Data are presented as mean ± SD. Statistical probability (P) was expressed as *P<0.05, ***P<0.001. ER, estrogen receptor; PR, progesterone receptor; HER, human
epidermal growth factor receptor.
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check the efficiency of primer pairs. RT-PCR data showed
that RNA were correctly transcribed from Seq#2 to Seq#7
(Seq#8 was a non-specific band because the size is incor-
rect) (Figure 2B). This data indicated that miR-183, miR-
96 and miR-182 were transcribed in the same pri-miRNA
and the start site of this pri-microRNA was 5352 bp to
3991 bp upstream of the miR-183 precursor, and the tran-
script termination site was 289 bp to 1352 bp downstream
of the miR-182 precursor. Several papers also predicted
that the TSS of miR-183/-96/-182 was between 5068 bp
and 5207 bp upstream of human miR-183 precursor
[16,18,19]. We could not tell whether the transcription
pattern was changed in cancer cells from this experiment
because the PCR method is not linear.
Next we sought to determine how this pri-miRNA was
regulated. To find the promoter region, we generated
luciferase reporters with 1 kb, 2 kb, 3 kb and 4 kb DNA
fragments within the conserved region (4263 bp to 8533 bp
upstream of the mouse miR-183 precursor, corresponding
to 5054 bp to 9324 bp upstream of the human miR-183
precursor. Figure 2A, red box), named upstream 1 kb, up-
stream 2 kb, upstream 3 kb and upstream 4 kb respectively.
These luciferase assay results showed that the upstream 1
kb, upstream 2 kb and upstream 3 kb fragments increased
luciferase activity approximately 30-fold compared with
the empty vector. No significant difference was detected
among upstream 1 kb, upstream 2 kb and upstream 3 kb.
Upstream 4 kb increased luciferase activity 17-fold
compared with the empty vector, which was much lower
than the other three reporters (Figure 2C). These dataTable 4 Correlation between miRNA levels and clinical stages
miR-96 (per million)
Stage I (n = 168) 39.6 ± 31.5
Stage II (n = 565) 44.1 ± 35.7
Stage III (n = 222) 38.6 ± 30.2
Stage IV and X (n = 33) 44.2 ± 34.2
The expression of each miRNA in the miR-183/-96/182 cluster in different breast can
first column. Data are presented as mean ± SD.demonstrate that most active regulatory elements were
located within 1 kb from the upstream of TSS region, and
some repression elements were located between 3 kb and
4 kb from upstream of the TSS region.
To find the transcription factors regulating the miR-
183/-96/-182 cluster, we used the online bioinformatics
tools TFSEARCH to predict the transcription factor
binding sites within 1 kb upstream from the TSS region
of the miR-183/-96/-182 cluster. Four DNA sequences
were predicted to be recognized by ZEB1, HSF2, ZEB1
and Sp1 respectively (Figure 3A). We mutated the can-
didate transcription factor binding sites and performed
the luciferase assay again. The luciferase activities of the
HSF2 and the first ZEB1 mutant were significantly lower
than upstream 1 kb (by about 50%), which suggested that
these two sites were indeed transcription factor binding
sites and that HSF2 and ZEB1 were two important
transcription factors in cluster transcriptional regulation
(Figure 3B). Therefore, we cloned HSF2 and ZEB1 into
the GV219 vector and co-transfected the transcription
factors and the native or mutated upstream 1 kb luciferase
reporters together into the MCF-7 cells. We found that
HSF2 alone upregulated the luciferase activity of native
upstream 1kb 1.9 (± 0.3)-fold, but had no effect on up-
stream 1 kb with a mutant HSF2 site. ZEB1 upregulated
the luciferase activity of native upstream 1 kb 6.7 (± 0.7)-
fold, but had no effect on ZEB1 mutant upstream 1 kb
reporter. There was no synergetic effect of these two
genes, as co-transfection of the two genes only upre-
gulated the luciferase activity of native upstream 1 kb 2.5
(± 0.2)-fold (Figure 3C).miR-182 (per million) miR-183 (per million)
48001.8 ± 29113.8 17783.2 ± 14764.5
49987.5 ± 37649.4 19919.8 ± 15730.5
47865.8 ± 29685.2 18164.0 ± 11961.5
47104.5 ± 29358.6 22262.4 ± 17792.5
cer subtypes based on their clinical stages: Patient number is indicated in the
Table 5 miRNA levels in different molecular subtypes of breast cancer
miR-96 (per million) miR-182 (per million) miR-183 (per million)
HER2-enriched (n = 34) 55.0 ± 46.9* 49308.2 ± 31807.6 24494.0 ± 16871.2*
Basal (n = 105) 42.3 ± 30.6 38971.0 ± 24170.6** 21991.9 ± 16491.6*
Luminal A (n = 406) 40.4 ± 35.5 50347.2 ± 34351.2 17668.1 ± 13604.2
Luminal B (n = 109) 38.0 ± 25.5 43312.6 ± 27928.1 17779.5 ± 13563.3
The expression of each miRNA in miR-183/-96/182 cluster in different molecular subtypes of breast cancer: Patient number is indicated in the first column. Data
are presented as mean ± SD. The following markers were used to determine breast cancer subtypes: luminal A (estrogen receptor (ER)+ and/or progesterone
receptor (PR)+, human epidermal growth factor (HER)2−), luminal B (ER + and/or PR+, HER2+), basal-like (ER−, PR− , HER2−), HER2-enriched (ER−, PR−, HER2+).
Statistical probability (P) was expressed as *P<0.05, **P<0.01.
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http://breast-cancer-research.com/content/16/6/473To further confirm our results, we transfected the
HSF2 and ZEB1 overexpression plasmids into MCF-7
cells, and then selected for stable cell lines with G418.
Then we compared the expression levels of miR-96,
miR-182 and miR-183 in stable overexpression cell lines
with the control cell line, which was transfected with
empty vector. Real-time PCR data showed that miR-96
and miR-183 were increased 2.7- to 3.8-fold compared
to the control cell line, but miR-182 did not increase very
much (Figure 3D). We think the reason why miR-182 didFigure 2 Analysis of the miR-183/-96/-182 cluster promoter region. (A
miR-183/-96/-182 cluster: sequences in the red box represent the region fro
is highly conserved and enriched for 3K27Ac histone marks. (B) Fragmenta
cluster was transcribed in the same pri-miRNA: upper panel shows a schem
miR-183/-96/-182 cluster in chromosome; lower panel shows the RT-PCR re
cell was used as a positive control to check the efficiency of primer pairs; R
was used as a negative control. (C) Luciferase assay indicated that most ac
the TSS region of miR-183/-96/-182 cluster. All luciferase activities were norm
represent SD (n = 4).not increase much is because miR-182 is far from the
transcript regulation area. Although these three miRNAs
are transcribed in the same pri-microRNA, the ending of
this pri-microRNA is not always the same. Sometimes,
it will end before miR-182 transcription. This result
might explain why miR-182 only increased 4.2 (± 1.1)-fold
in tumor samples, but miR-96 and miR-183 increased 8.4
(± 1.1)- and 7.5 (± 1.1)-fold in tumor samples. It could
also explain why the expression levels of miR-183 and
miR-182 correlated more strongly sin normal samples, but) ENCODE project analysis of the upstream sequence of the
m 5054 bp to 9324 bp upstream of the human miR-183 precursor that
l reverse transcription (RT)-PCR demonstrated that the miR-183/-96/-182
atic representation of the location of RT-PCR fragments and the
sults of MCF-10A, MCF-7 and T47D cell cDNAs. Genomic DNA of MCF-7
NA sample, which did not undergo the reverse transcription reaction,
tive regulatory elements were located within 1 kb from upstream of
alized to those obtained with the pGL3-Basic vector alone. Error bars
Figure 3 Identification of the transcription factors regulating the miR-183/-96/-182 cluster. (A) Phylogenetic analysis demonstrated that
there were four conserved transcription factor binding sites located within the 1 kb region upstream of the TSS of the miR-183/-96/-182 cluster in
vertebrates. (B) Luciferase activities were decreased after mutation of the first ZEB1 and HSF2 transcription factor binding sites. All luciferase
activities were normalized to those obtained with the pGL3-Basic vector alone. Error bars represent SD (n = 3). (C) Transfection of ZEB1 and HSF2
transcription factors could elevate the luciferase activity of native upstream 1 kb luciferase reporter but not its mutants. All luciferase activities
were normalized to those obtained with the native upstream 1 kb alone. Error bars represent standard deviation (n = 3). (D) Real-time PCR
showing that miR-96 and miR-183 levels were increased in ZEB1 and HSF2 overexpressing MCF-7 cell lines. U6 snRNA was used as internal control.
Error bars represent SD (n = 3).
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Because the transcription of miR-183/-96/-182 was so fast
in cancer, some pri-miRNA was not complete.
Up-regulation of the miR-183/-96/-182 cluster increased
cell proliferation and migration and changed the cell
cycle profile
To investigate the biological effects of miR-183/-96/-182
cluster up-regulation in the development and progression
of breast cancer, we generated miR-96, miR-182 and miR-
183 overexpression cell lines in both MCF-7 and T47D
cells (Additional file 1: Figure S1). Using MTT assays, we
observed that the growth rates of all overexpression cell
lines were increased as compared with that of empty vector
control or non-transfected cells in both MCF-7 and T47D
cells (Figure 4A). Furthermore, in colony formation assays,
the increase of colony numbers in MCF-7 overexpressioncell lines indicated that ectopically expression of the miR-
183/-96/-182 cluster in MCF-7 cells significantly enhanced
anchorage-independent growth (Figure 4B). Furthermore,
in both MCF-7 and T47D cells, in vitro wound-healing as-
says demonstrated that the migration abilities of miR-183,
miR-96, and miR-182 overexpression cell lines were ele-
vated, as the non-healed areas were smaller in overexpres-
sion cell lines than in control (empty vector) or non-
transfected cells (Figure 4C).
To further explore the ability of the miR-183/-96/-182
cluster to promote cell proliferation, we analyzed the cell
cycle profile of these overexpression cell lines. In both
MCF-7 and T47D cells, flow cytometry results showed a
small but significant decrease in the percentage of cells
in the G2/M peak and a small but significant increase in
the percentage of cells in the G1/G0 peak, the percentage
of cells in the S phase was unaltered (Figure 5). These data
Figure 4 Up-regulation of the miR-183/-96/-182 cluster increased cell proliferation and migration. (A) The 3-(4, 5-dimethyl-2-thiazolyl)-2,
5-diphenyl-2H-tetrazolium bromide (MTT) assays showed that miR-183/-96/-182 cluster overexpression cell lines proliferated more rapidly than the
vector control and non-infected cells. Error bars represent SD (n = 4). (B) Micrographs (left) and quantification (right) of crystal violet-stained cell
colonies in miR-183/-96/-182 cluster overexpression MCF-7 cell lines and the vector control cells. Error bars represent SD (n = 4). (C) Cell wound-healing
assays demonstrated that the migration abilities of overexpression cell lines were elevated: left panel, representative micrographs; right panel,
quantification graph; upper panel, MCF-7 cells; lower panel, T47D cells. Error bars represent SD (n = 4). Scale bars: 100 μm.
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cell proliferation by promoting more rapid completion of
mitosis.
Inhibition of miR-183/-96/-182 cluster miRNAs decreased
cell proliferation, and even induced cell death
To explore the knockdown effects of miR-183/-96/-182
cluster miRNAs, we transfected the miR-Down™ antago-
mirs to the MCF-7 and T47D cells. First, we checked the
knockdown efficiency and specificity of these antagomirs.
Real-time PCR data showed that each antagomir knocked
down its corresponding miRNA efficiently in both MCF-7
and T47D cells. MiR-182 antagomir also slightly decreased
miR-96 expression, except that there were no cross-
reactions. The knockdown efficiency was higher in MCF-7
cells than in T47D cells, and miR-96 antagomir and miR-
182 antagomir were more efficient than miR-183 antago-
mir (Figure 6A). Then, we checked the cell growth rates,
cell migrations and cell cycle profiles of these knockdown
cells by MTT assay, cell wound-healing assay and cell
cycle analysis. MTT assay data showed that knockdown ofmiR-96 and miR-182 decreased the cell growth rates sig-
nificantly in both MCF-7 and T47D cells. The growth rate
of miR-183 antagomir-treated cells also decreased slightly,
but the decrease was not significant (Figure 6B). In
MCF-7 cells, the migration abilities of knockdown cells
were all decreased although the decrease was not sig-
nificant for miR-183 antagomir-treated cells. However, in
T47D cells, only the miR-182 antagomir led to the de-
crease of migration; the migration ability of miR-96
and miR-183 antagomir-treated cells remained the same
(Figure 6C). Furthermore, cell cycle analysis demonstrated
a significant increase in G2/M phase and a decrease in S
phase for cells treated with miR-182 antagomir in MCF-7
cells. Knockdown of miR-96 also decreased the percentage
of cells in S phase slightly in MCF-7 cells, but in T47D
cells the cell cycle profiles were not changed except for a
slight increase in G2/M phase after miR-182 antagomir
treatment (Figure 6D). We think the different behavior of
MCF-7 and T47D cells after antagomir treatment was
related to the knockdown efficiency. As the knockdown
efficiency was higher in MCF-7 cells, the growth rate and
Figure 5 Up-regulation of miR-183/-96/-182 cluster miRNAs changed the cell cycle profile. Flow cytometric analysis showed a significant
decrease in the percentage of cells in the G2/M peak and an increase in the percentage of cells in the G1/G0 peak of miR-183/-96/-182 cluster
overexpression cell lines compared with the vector control cells and non-infected cells. (A) Representative flow cytometric graph of each cell line.
(B) Quantification graph of the flow cytometric analysis. Error bars represent SD (n = 3).
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by the antagomir. Knockdown of miR-183 did not affect
the cell profiles too much either in MCF-7 or in T47D
cells. This phenomenon could be explained by the ineffi-
cient knockdown and the compensatory effect. MiR-96
and miR-182 might have substituted partial function of
miR-183 and compensated the loss of miR-183.
To further examine the biological effect of the miR-
183/-96/-182 cluster as a whole on breast cancer cells,
we generated miR-183/-96/-182 cluster sponge lentivirus
(Additional file 2: Figure S2), and infected T47D cells with
this vector. First, we checked the inhibition efficiency of
this virus by real-time PCR. Compared to the empty vec-
tor, the expressions of miR-183/-96/-182 cluster miRNAs
were dropped to a half after sponge lentivirus transduc-
tion; and the expression of FOXO1, which was a generally
acknowledged target gene of the miR-183/-96/-182 cluster,
was increased about 2-fold after sponge lentivirus trans-
duction (Figure 6F upper panel). We found that T47D
cells underwent cell death and apoptosis after trans-
duction. Three days after transduction, the cells be-
came round and detached (Figure 6E). Cell cycle analysis
showed an increase in the percentage of cells in the G2/M
peak and pre-G1 peak and a decrease in the percentage of
cells in the G1/G0 peak, indicating that inhibition of
miR-183/-96/-182 induced G2/M arrest and apoptosis
(Figure 6F lower panel).As MCF-7 and T47D cells are both luminal breast
cancer, we also tested the miRNA knockdown effects in
basal-like breast cancer cells, such as BT-20 (Basal A)
and MDA-MB-231 (Basal B) cells. We found basal-like
cells were more sensitive to the depletion of the miR-
183/-96/-182 cluster than the luminal-like cells. MTT
experiments showed BT-20 ceased proliferation and un-
derwent cell death after knockdown of miR-96, miR-182 or
miR-183 (Additional file 7: Figure S4A, B). MDA-MB-231
cells underwent cell death and apoptosis after transduction
of miR-183/-96/-182 cluster sponge lentivirus. The cells
became round and detached 3 days after transduction,
and the cell cycle analysis showed that pre-G1 cells, which
represented the apoptotic cells, were increased in knock-
down cells (Additional file 7: Figure S4C, D).
MiR-183 targeted the RAB21 gene directly in breast cancer
To better understand the biological roles of the miR-183/-
96/-182 cluster miRNAs in breast cancer, we compiled a
list of putative target genes of the miR-183/-96/-182
cluster that were dysregulated in breast cancer by using
three computational target prediction-algorithms: PicTar,
TargetScan 5.1 and MicroCosm (Additional file 4: Table S2).
As mammalian miRNAs regulate target genes predomin-
antly by acting to decrease target mRNA levels [24], we
first compared the mRNA levels of those genes between
breast cancer sample and its NAT by real-time PCR with
Figure 6 Inhibition of miR-183/-96/-182 cluster miRNAs decreased cell proliferation, and even induced cell death. (A) Real-time PCR
results showed the knockdown efficiency and specificity of miR-Down™ antagomirs: left panel, MCF-7 cells; right panel, T47D cells. U6 snRNA was
used as internal control. Error bars represent SD (n = 4). (B) The 3-(4, 5-dimethyl-2-thiazolyl)-2, 5-diphenyl-2H-tetrazolium bromide (MTT) assays
showed the cell growth rates of miR-183/-96/-182 cluster knockdown cells. Error bars represent SD (n = 4). (C) Cell wound-healing assays showed
the migration abilities of miR-183/-96/-182 cluster knockdown cells. Error bars represent SD (n = 4). (D) Flow cytometric analysis of miR-183/-96/-182
cluster knockdown cells. Error bars represent SD (n = 3). (E) T47D cells infected with miR-183/-96/-182 cluster sponge lentivirus underwent
apoptosis 3 days after transduction: left panels, phase-contrast micrographs of indicated cells; right panels, green fluorescent micrographs of
indicated cells. Scale bars: 20 μm. (F) Analysis of miR-183/-96/-182 cluster sponge lentivirus-infected T47D cells: upper panel, inhibition efficiency
of miR-183/-96/-182 cluster sponge lentivirus shown by real-time PCR (error bars represent SD, n = 4; lower panels, flow cytometric graph of
indicated cells.
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twenty-five candidates showed significantly decreased ex-
pression in breast cancer (Figure 7A). To validate the eight
candidates, we checked their mRNA levels in the miR-96,
miR-182 and miR-183 MCF-7 overexpression cell lines.Compared to empty vector control cells, RAB21 was de-
creased in the miR-183 overexpression cell line; RAB40B
was decreased in miR-96 and miR-183 overexpression cell
lines and TNFSF11 was decreased in the miR-96 overex-
pression cell line (Figure 7B).
Figure 7 Identification of candidate targets of miR-183/-96/-182 cluster miRNAs. Predicted miR-183/-96/-182 targets are listed in Additional
file 4: Table S2 where their NCBI reference sequence, putative binding miRs and detection primers are also provided. (A) Comparison of candidate
target mRNA levels between breast cancer samples and their normal adjacent tissue (NAT) by real-time PCR; glyceraldehyde-3-phosphate
dehydrogenase (GAPDH) was used as an internal control. Error bars represent SD (n = 3). (B) Confirmation of target genes by real-time PCR in
miR-183/-96/-182 cluster overexpression stable MCF-7 cell lines and control cells; GAPDH was used as an internal control. Error bars represent SD
(n = 3). (C) Confirmation of miR-183/-96/-182 cluster targets by luciferase assay. All data were normalized to those obtained with the pGL3-Promoter
vector alone. Error bars represent SD (n = 3): lower panel, sequences of miR-183 and its target sequences in the 3′-UTR of different species. (D) Protein
levels of RAB21 in stable cell lines were documented by western blot with an anti-RAB21 antibody. β-Tubulin was used as the internal control; upper
panel, MCF-7 cells; lower panel, T47D cells. (E) Phalloidin and 4',6-diamidino-2-phenylindole (DAPI) counterstaining results showed that the bi- and
multinuclear cells were accumulated in miR-183 over-expressed MCF-7 cells; left panels, representative micrographs of single, bi- and multinuclear cells
in both interphase and mitosis; right panel, quantification of bi- and multinuclear cells in different cell lines. Error bars represent SD (n = 5). Scale bars:
10 μm.
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183, we focused our efforts on this target. RAB21, which
belongs to the Rab family of monomeric GTPases, plays
a role in integrin internalization and recycling. As a result,
the encoded protein is involved in cytokinesis during
the mitosis. Loss of RAB21 in the tumor induces chromo-
some number aberrations and malignancy [25]. To further
evaluate the role of miR-183 in regulating RAB21, we
generated luciferase reporters with 33 bp of the predicted
target regions from the 3′-UTR of RAB21, and co-trans-
fected the reporter with miR-96, miR-182 and miR-183overexpression vectors and empty vector. The luciferase
assay results showed that miR-183 repressed luciferase
activity dramatically in the reporter derived from the
RAB21-targeted region compared with the empty vector,
and miR-96 and miR-182 had no effect on the luciferase
activity of the RAB21 reporter. As a negative control, the
luciferase activity of cells containing the empty pGL3-
Promoter vector was not affected by any miR-183/-96/-
182 cluster miRNA (Figure 7C). The protein levels of
RAB21 were also determined in both MCF-7 and T47D
overexpression cell lines with β-tubulin used as an internal
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cantly decreased in the miR-183 overexpression cell lines,
but not in miR-96 and miR-182 overexpression cell lines
compared with the empty vector control cell lines and
wild-type cells (Figure 7D). As loss of RAB21 in the
tumor would induce chromosome number aberrations,
we checked the nucleus aberration in miR-183/-96/-182
cluster overexpression MCF-7 cells. Phalloidin and DAPI
counterstaining results showed that the bi- and multinu-
clear cells were accumulated in miR-183 overexpressed
cells but not in miR-96 and miR-182 overexpressed cells
(Figure 7E). All these data indicated that miR-183 targeted
the RAB21 gene directly in breast cancer and induced
aneuploidy.
Discussion
The MiR-183/-96/-182 cluster is a conserved polycis-
tronic miRNA cluster that is highly expressed in several
tumor types. Although it is well known that the expres-
sion level of this miRNA cluster is increased in breast
cancer, its biological roles and the regulatory mecha-
nisms governing MiR-183/-96/-182 expression in breast
cancer are still unclear. Here, we report that miR-96,
miR-182 and miR-183 expression levels are significantly
higher in breast cancer compared to the NAT, and the
transcription pattern of miR-183/-96/-182 is irregular in
breast cancer as the correlation between miR-182 and
miR-183 expression dropped dramatically in tumor
samples. The expression of miR-183/-96/-182 is not
upregulated in a specific breast cancer subtype. It is
overexpressed in all kinds of breast cancer - ductal or
lobular, luminal or basal, early-stage or late-stage - but
there are some differences in their expression patterns.
For example, miR-96 and miR-183 were lower in lobular
carcinoma than in ductal carcinoma and other types of
carcinoma. The levels of miR-96 and miR-183 were also
lower in ER+ and PR+ cancers than in ER− and PR− can-
cers, but miR-182 was almost the same, even a little higher
in ER+ cancers. Among the four different subtypes of
breast cancer, miR-96 and miR-183 levels were higher in
HER2-enriched breast cancers than other types; miR-182
was lower but miR-183 was higher in basal-like breast
cancers than other types of breast cancer. We also com-
pared the miRNA expression levels in different breast can-
cer cell lines based on their molecular markers. We found
that miR-96 is only upregulated in SK-BR-3 and BT-20
cells, whereas miR-182 and miR-183 are upregulated in
most of the breast cancer cell lines tested except for
MDA-MB-231. Basically, the cell line data closely match
the clinical analysis. MiR-96 and miR-183 levels are higher
in HER2-enriched cell line SK-BR-3. MiR-96 is lower in
ER+ and PR+ cancers than in ER− and PR− cancers.
MiR-182 is higher in luminal breast cancer than basal
breast cancer. MDA-MB-231 is the only exception. Itis an ER− and PR− cancers, but its expression of miR-
183/-96/-182 is low. Because MDA-MB-231 is a basal B/
claudin-low breast cancer cell line, which lacks common
epithelial cell features and most closely resembles the
mammary epithelial stem cell [26], we think its regulation
of miR-183/-96/-182 is different to other breast cancer cell
lines. Our data were similar to those reported by Riaz and
colleagues. Based on their work, 51 human breast cancer
cell lines were divided into two groups: the first major
group included 33 cell lines, which was a luminal-like
group; the second minor group included 18 cell lines,
which was a basal-like group. Seventeen miRNAs, which
included miR-182, showed significantly higher expression
in the major cluster compared with the other miR-
NAs. They also found that the expression of miR-183/-
96/-182 is low in MDA-MB-231 cells [23]. Although the
miR-183/-96/-182 cluster is transcribed in the same pri-
miRNA, the expression profile of each miRNA varies
between different cell lines, which indicate that their sub-
sequent processing or stability are regulated in different
ways. An interesting phenomenon is that from the 102
patient samples of TCGA dataset, miR-182 only increases
4.2 (± 1.1)-fold in tumor samples, but miR-96 and miR-
183 increase 8.4 (± 1.1)- and 7.5 (± 1.1)-fold in tumor
samples. The correlation between the expressions of miR-
182 and miR-183 dropped dramatically in tumor samples.
This phenomenon was also confirmed in HSF2 and ZEB1
overexpression cell lines, as the expressions of miR-96 and
miR-183 were increased significantly, but not miR-182.
We think it is because the transcription of miR-183/-96/-
182 is very fast in cancer; some pri-miRNA is not
complete and the transcription stalls before miR-182.
We also identified two transcriptional factors that regu-
late the transcription of the miR-183/-96/-182 cluster, ZEB1
and HSF2. ZEB1, which is a zinc finger transcription factor,
is involved in the epithelial-mesenchymal transition and
promotes metastasis in cancer [27,28]. Although most work
has concentrated on the capacity of ZEB1 to repress gene
expression, several groups demonstrated that ZEB1 can also
activate transcription of downstream targets [28,29]. HSF2
binds heat shock promoter elements (HSE) and activates
transcription. Although there is little evidence on the
involvement of HSF2 in tumorigenesis, it can play a role
indirectly by modulating HSF1 [30]. Previous studies
also report that HSF2 regulates the proto-oncogene c-fos
and may be involved in tumorigenesis [31]. Our findings
show that ZEB1 and HSF2 activate the transcription of the
miR-183/-96/-182 cluster, which gives us new insights into
how ZEB1 and HSF2 enhance tumorigenesis.
The biological role of the miR-183/-96/-182 cluster in
breast cancer is complicated. In our experience, this clus-
ter functions more like an oncogene in breast cancer as it
increases cancer cell proliferation and migration. Most
previous and recent publications support this conclusion,
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many groups to induce breast cancer metastasis [6,32-34].
Mir-96 is also proposed to be an onco-miRNA in breast
cancer [5,6], but the role of miR-183 is more complex. It
represses the expression of EGR1 and functions as an
oncogene in breast cancer [35], but it also targets the
Ezrin gene and inhibits cell migration in T47D cells [12].
Our results support a pro-oncogenic role for miR-183 in
breast cancer, because upregulated expression of miR-183
by lentivirus in MCF-7 cells induces cell proliferation and
migration. The effects of knockdown of miR-183/-96/-182
cluster are more complicated, and depend on the knock-
down efficiency and specificity. We did not observe obvi-
ous changes after inhibition of miR-183, but we found a
significant decrease in cell growth rates and S phase cell
percentages in miR-96 and miR-182-inhibited cells. Two
reasons can explain these results. First, the knockdown
efficiency of miR-183 antagomir is lower than miR-96 and
miR-182 antagomir. Second, miR-96 and miR-182 target
FOXO1, but miR-183 does not [6]. MiR-96 and miR-182
might compensate partial functions of miR-183, but miR-
183 cannot replace the function of miR-96 and miR-182
on inhibition of FOXO1.
Long-term inhibition of three miRNAs by sponge ele-
ments induced cell death and apoptosis in T47D cells,
but we did not detect apoptosis with a single antagomir
transfection. Inhibition of two or three of the cluster
members at one time induced apoptosis, though some of
them were not statistically significant (Additional file 8:
Figure S5). These data indicate that these three miRNAs
are redundant; they may be complimentary to each other.
Knockdown of miR-183 had little effect on its own, but it
had collaborative effects with the other two miRNAs.
We identified RAB21 as a target gene of miR-183 in
both mRNA and protein levels, and also confirmed that
overexpression of miR-183 induced accumulation of bi-
and multinuclear cells. RAB21 is involved in the targeted
trafficking of integrins via its association with integrin
alpha tails. As a consequence, RAB21 regulates cell adhe-
sion and migration [36]. In mitotic cells, integrin traffick-
ing regulated by RAB21 is necessary for cytokinesis and
cytokinesis failure will induce aneuploidy and oncogenic
transformation [25,37]. This information may answer the
question why miR-183 has dual effects in breast cancer. In
some cases, repression of RAB21 results in decreased cell
mobility, but in other cases, repression of RAB21 may lead
to cytokinesis failure and aneuploidy. The 3′-UTR of
RAB21 matches the seed sequence of miR-183, but not
miR-96 nor miR-182. So, only miR-183 can inhibit the
expression of RAB21. As the phenotype is similar no
matter which of the three miRNAs is overexpressed in
MCF-7 and T47D cells, RAB21 down regulation itself is
not enough to explain the phenotype. Some other me-
chanisms are also involved in the regulation of cellproliferation and migration. For example, inhibition of
FOXO1 by miR-96 and miR-182 will increase cell
proliferation.
We identified two regulators (ZEB1 and HSF2) and one
target gene (RAB21) for the miR-183/-96/-182 cluster in
breast cancer cell lines. How do they work in clinical sam-
ples? We looked for correlation between miR-183/-96/-182
cluster miRNAs and their target/regulators by analysis of
508 clinical samples from TCGA data (Additional file 9).
Because the correlations between miRNAs and their
targets/regulators are not simply negative or positive
correlations, we did not find any direct correlations be-
tween these miRNAs and the expressions of HSF2, ZEB1
and RAB21 based on the TCGA data analysis. But there
were some interesting correlations between them in dif-
ferent subtypes. MiR-96 and miR-183 weree lower in ER+
and PR+ breast cancers than ER− and PR− breast cancers;
in the meantime, their regulator, HSF2 level was lower
and their target, RAB21 level, was higher in ER+ and
PR+ breast cancers than ER− and PR− breast cancers
(Additional file 4: Table S4). Subtype analysis also con-
firmed our findings. HSF2 level was high in basal breast
cancers, which are miR-183-enriched breast cancers; and
RAB21 level was low in HER2 and basal breast cancers,
which are miR-96- and/or miR-183-enriched breast cancers
(Additional file 4: Table S5). MiR-182 was not strongly
correlated with the levels of HSF2 because its transcription
is not controlled by HSF2 (Figure 3D). There is still a com-
plicated phenomenon that requires explanation, which is
that the ZEB1 level was negatively correlated with miR-96
and miR-183 (Additional file 4: Table S4, S5). In MCF-7
cells, ZEB1 upregulates the expressions of miR-96 and
miR-183 (Figure 3), and Graham et al. also report that
ZEB1 is more expressed in ER/PR− breast cell lines than
ER/PR+ breast cell lines [38]. However, in clinical samples,
ZEB1 was enriched in ER/PR+ samples. Considering ZEB1
is a transcription factor that can either activate or repress
its target genes, we think it functions differently in breast
cancer cell lines and breast cancer patients. In patients,
ZEB1 may repress the transcription of miR-183/-96/-182
cluster. This conclusion needs further work for confirm-
ation, but nevertheless, ZEB1 plays an important role in
the regulation of miR-183/-96/-182 cluster.
Conclusion
We found that the miR-183/-96/-182 cluster is highly
expressed in most breast cancers, and its transcription is
disordered in breast cancers. The miR-183/-96/-182 cluster
is transcribed in the same pri-miRNA and its transcription
is regulated by ZEB1 and HSF2. It increases breast cancer
cell proliferation, promotes cell migration and is essential
for cell survival. Also, miR-183 targets the RAB21 gene dir-
ectly in breast cancer. In summary, the miR-183/-96/-182
cluster is upregulated in most breast cancers. It functions as
Li et al. Breast Cancer Research 2014, 16:473 Page 16 of 17
http://breast-cancer-research.com/content/16/6/473an oncogene in breast cancer as it increases cell prolifera-
tion and migration. This can be partially explained by the
inhibition of tumor suppressor gene RAB21.
The bioinformatics tools used in this manuscript were
the miRBase Sequence Database [39]; the TCGA dataset
[40]; the ENCODE Project [41]; TFSEARCH [42]; Pic-
Tar [43]; TargetScan 5.1 [44], and MicroCosm [45].
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